With the novel COVID-19 virus continuing to spread, it is crucial to adhere to the advice from experts and the Centers for Disease Control and Prevention (CDC) to help reduce risk of infection for individuals and the population at large. This is particularly important for people with adrenal insufficiency and people with uncontrolled Cushing’s Syndrome.

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.

In the systematic review and meta-analysis of more than 4,000 patients with adenomas published in the Annals of Internal Medicine (Elhassan et al), authors reported that patients with mild autonomous cortisol secretion or nonfunctioning adrenal adenomas very rarely develop overt hormonal excess (<0.1%). In addition, adenoma growth >1cm occurred only in 2.5% of patients and no patient developed an adrenal malignancy at follow up.

The use of an insulin pump to deliver continuous pulsatile cortisol may be a viable treatment option in patients with severe adrenal insufficiency who are unresponsive to oral corticosteroids, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

Biochemical markers and clinical signs and symptoms of endogenous Cushing syndrome improved after 6 months of levoketoconazole therapy, according to phase 3 study results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

Distinctive serum steroid profiles might emerge in patients with adrenal tumors and Cushing's syndrome, according to research reported by Shobana Athimulam, MBBS, of the Mayo Clinic in Rochester, Minnesota, and colleagues, at the AACE 28^th Annual Scientific & Clinical Congress.

The investigational agent relacorilant significantly improved excess cortisol in patients with endogenous hypercortisolism, researchers reported at the AACE 28^th Annual Scientific & Clinical Congress.